CRBP - Corbus Pharmaceuticals Holding logo

Corbus Pharmaceuticals Holding

CRBP

Corbus Pharmaceuticals develops therapeutics for cancer and obesity, including CRB-701, an antibody drug conjugate targeting Nectin-4 in cancer cells, and CRB-913, a cannabinoid receptor inverse agonist for obesity treatment.

⚕️ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago →$16today

Score Overview

1 Year
Score—
Net Growth-29.75%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
Score2.1
Net Growth-123.70%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
10 Years
Score
Net Growth-409.55%
Net Trend30%
Net Income Consistency
Rev Growth-100.00%
Rev Trend30%
Revenue Consistency
All Time
Score—
Net Growth-38x
Net Trend25%
Net Income Consistency
Rev Growth—
Rev Trend42%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Corbus Pharmaceuticals Holding has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CRBP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-21
$ 4.29—
1 Year2025-10-21
$ 19.36-77.87%
5 Years2021-10-21
$ 30.90-86.13%
10 Years2016-10-21
$ 268.50-98.40%
All Time2014-11-11
$ 90.00-95.24%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 101M$ 117M
2025$ 0.00-$ 78M$ 163M
2024$ 0.00-$ 40M$ 149M
2023$ 0.00-$ 44M$ 20M
2022$ 0.00-$ 55M$ 59M
2021$ 881.71K-$ 45M$ 97M
2020$ 3M-$ 111M$ 85M
2019$ 36M-$ 71M$ 31M
2018$ 4M-$ 55M$ 41M
2017$ 2M-$ 32M$ 62M
2016$ 1M-$ 19M$ 14M
2015$ 648.38K-$ 8M$ 12M
IPO2014$ 0.00-$ 2M$ 6M
CRBP - Corbus Pharmaceuticals Holding logo

Corbus Pharmaceuticals Holding fundamental performance

Between 2020 and 2025, revenue declined from $ 3M to $ 0.00 and net income went from -$ 111M to -$ 78M. Revenue increased in 0 of those 5 years; net income in 2.

Between 2015 and 2025, revenue declined from $ 648.38K to $ 0.00 and net income went from -$ 8M to -$ 78M. Revenue increased in 3 of those 10 years; net income in 3.

Corbus Pharmaceuticals Holding currently holds a 5-year HDB Score of 2.1 out of 10. How the HDB Score is calculated.

Membership

Explore CRBP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,118 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies